Cara Therapeutics to merge with Tvardi Therapeutics.

Cara Therapeutics, a clinical-stage biopharmaceutical company, agreed to merge with Tvardi Therapeutics, a privately held company developing novel therapies targeting STAT3 for fibrosis-driven diseases. Financial terms were not disclosed. “As we approach meaningful value inflection points next year, including two Phase 2 readouts of our lead program in idiopathic pulmonary fibrosis, followed by the readout in our hepatocellular carcinoma program, this merger, the recently completed financing, and becoming a publicly traded company give us access to the critical funding required to further advance our promising pipeline programs that address significant unmet needs. I am grateful to the Cara Board, leadership team, and shareholders who share our vision of Tvardi that is well-positioned to introduce effective, new treatment options to patients suffering from serious, chronic, fibrosis-driven diseases," Imran Alibhai, Tvardi CEO.